Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus AMINOSYN RF 5 2.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN HBC 7 IN PLASTIC CONTAINER versus AMINOSYN RF 5 2.
AMINOSYN-HBC 7% IN PLASTIC CONTAINER vs AMINOSYN-RF 5.2%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Provides essential and nonessential amino acids to support protein synthesis and nitrogen balance in patients with metabolic stress or hepatic encephalopathy.
Aminosyn-RF 5.2% is an amino acid solution that provides essential and nonessential amino acids for protein synthesis, primarily in patients with renal impairment. It is designed to reduce ureagenesis and nitrogenous waste accumulation by supplying a higher proportion of essential amino acids while limiting total nitrogen load.
1-2 L/day intravenously (equivalent to 70-140 g amino acids/day) for adults; infuse at no more than 0.1 g/kg/h.
1-1.5 g/kg/day intravenously as a continuous infusion, typically 500 mL to 1000 mL/day depending on amino acid requirements and fluid status. Dose is expressed as grams of amino acids per kg of ideal body weight per day.
None Documented
None Documented
Terminal elimination half-life of infused amino acids is approximately 0.5-1 hour for free amino acids, but varies by individual amino acid. Clinical context: rapid clearance in critically ill patients due to increased metabolic demand.
The terminal elimination half-life of infused amino acids is approximately 10–20 minutes, reflecting rapid distribution and metabolism; clinical context: continuous infusion maintains steady state within 30 minutes.
Renal: 100% of infused amino acids are metabolized or excreted renally as urea and other nitrogenous waste products. No biliary or fecal elimination.
Primarily renal; >95% of infused essential amino acids and small peptides are reabsorbed; excess amino acids are deaminated and nitrogen excreted as urea in urine (renal clearance of urea). Biliary/fecal excretion is negligible (<2%).
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution